Newsroom

Sight Sciences Strengthens Its Leadership Team with Chief Operating Officer and General Counsel Hires

Industry veterans will lead scaling of company operations and processes to support OMNI Surgical System and TearCare growth

read more +
Sight Sciences Announces Publication of Historical Review of Canal Surgery in the Glaucoma Issue of Current Opinion in Ophthalmology

MENLO PARK, Calif., March 30, 2020 /PRNewswire/ -- Sight Sciences, Inc., a growth-stage medical device company focused on transforming the treatment of glaucoma and dry eye disease, today announced that a review of the history of canal surgery in glaucoma, by Jaime Dickerson, Ph.D., and Reay Brown, M.D., has been published in Current Opinion in Ophthalmology.

read more +
Sight Sciences Announces $30 Million Financing Led by D1 Capital Partners

MENLO PARK, Calif., March 18, 2020 /PRNewswire/ — Sight Sciences, Inc., a growth-stage medical device company transforming the two fastest growing segments in ophthalmology and optometry, glaucoma and dry eye disease, today announced the closing of an over $30 million Series E Preferred Stock financing round led by D1 Capital Partners. Proceeds will be used for continued clinical and […]

read more +
Sight Sciences Announces Publication of First-Ever Multicenter MIGS study in Childhood Glaucoma

Sight Sciences, Inc., a growth-stage medical device company transforming the two fastest-growing segments in ophthalmology and optometry, glaucoma and dry eye disease, today announced that positive outcomes from a new multicenter study of one of the OMNI® Surgical System’s predecessor devices, TRAB®360, were published in the American Journal of Ophthalmology.   Following a 2019 publication1 of a […]

read more +
Event: Congress of German Ophthalmic Surgeons (DOC)

Event Details June 17-19 Nuremberg, Germany Contact Sight Sciences today to schedule a meeting.

read more +
Event: European Society of Cataract and Refractive Surgeons (ESCRS)

Event Details August 27-30 Amsterdam, Netherlands Contact Sight Sciences today to schedule a meeting.

read more +
Event: World Glaucoma Congress (WGC)

Event Details June 30- July 3 VIRTUAL Contact Sight Sciences today to schedule a meeting.

read more +
Event: European AECOS

Event Details June 3-6 Florence, Italy Contact Sight Sciences today to schedule a meeting.

read more +
Sight Sciences Receives Full Investigational Device Exemption (IDE) Approval from the US FDA to Initiate the VISCO™360 Versus SLT Glaucoma Trial

Sight Sciences, Inc., a venture-backed, commercial-stage ophthalmic medical device company announced today that it has received full IDE approval from the FDA to initiate the world’s first clinical trial comparing ab interno canaloplasty with selective laser trabeculoplasty. Study will evaluate the safety and effectiveness of an ab interno procedure for patients with primary open angle […]

read more +